O	0	8	Research	Research	NN	B-NP
O	9	12	and	and	CC	I-NP
O	13	22	discovery	discovery	NN	I-NP
O	23	25	of	of	IN	B-PP
O	26	29	the	the	DT	B-NP
O	30	35	first	first	JJ	I-NP
O	36	41	human	human	JJ	I-NP
B-Cancer	42	48	cancer	cancer	NN	I-NP
O	49	54	virus	virus	NN	I-NP
O	54	55	,	,	,	O
O	56	60	HTLV	HTLV	NN	B-NP
O	60	61	-	-	HYPH	B-NP
O	61	62	1	1	CD	I-NP
O	62	63	.	.	.	O

O	65	70	Human	Human	JJ	B-NP
O	71	72	T	T	NN	I-NP
O	72	73	-	-	HYPH	I-NP
O	73	77	cell	cell	NN	I-NP
O	78	86	lymphoma	lymphoma	NN	I-NP
O	87	92	virus	virus	NN	I-NP
O	93	94	(	(	(	O
O	94	98	HTLV	HTLV	NN	B-NP
O	98	99	)	)	)	O
O	99	100	-	-	HYPH	B-NP
O	100	101	1	1	CD	I-NP
O	102	105	was	be	VBD	B-VP
O	106	109	the	the	DT	B-NP
O	110	115	first	first	JJ	I-NP
O	116	121	human	human	JJ	I-NP
O	122	132	retrovirus	retrovirus	NN	I-NP
O	133	135	to	to	TO	B-VP
O	136	138	be	be	VB	I-VP
O	139	149	discovered	discover	VBN	I-VP
O	149	150	.	.	.	O

O	151	153	It	It	PRP	B-NP
O	154	157	has	have	VBZ	B-VP
O	158	162	been	be	VBN	I-VP
O	163	173	recognized	recognize	VBN	I-VP
O	174	176	as	as	IN	B-PP
O	177	180	the	the	DT	B-NP
O	181	186	cause	cause	NN	I-NP
O	187	189	of	of	IN	B-PP
B-Cancer	190	195	adult	adult	JJ	B-NP
I-Cancer	196	197	T	T	NN	I-NP
I-Cancer	197	198	-	-	HYPH	B-NP
I-Cancer	198	202	cell	cell	NN	I-NP
I-Cancer	203	211	leukemia	leukemia	NN	I-NP
O	212	213	(	(	(	O
B-Cancer	213	216	ATL	ATL	NN	B-NP
O	216	217	)	)	)	O
O	217	218	.	.	.	O

O	219	221	In	In	IN	B-PP
O	222	230	addition	addition	NN	B-NP
O	231	233	to	to	TO	B-PP
O	234	240	giving	give	VBG	B-VP
O	241	242	a	a	DT	B-NP
O	243	253	historical	historical	JJ	I-NP
O	254	265	perspective	perspective	NN	I-NP
O	266	268	on	on	IN	B-PP
O	269	273	HTLV	HTLV	NN	B-NP
O	273	274	-	-	HYPH	B-NP
O	274	275	1	1	CD	I-NP
O	276	279	and	and	CC	O
O	280	285	other	other	JJ	B-NP
O	286	296	retrovirus	retrovirus	NN	I-NP
O	297	305	research	research	NN	I-NP
O	305	306	,	,	,	O
O	307	311	this	this	DT	B-NP
O	312	317	paper	paper	NN	I-NP
O	318	327	discusses	discuss	VBZ	B-VP
O	328	331	the	the	DT	B-NP
O	332	338	origin	origin	NN	I-NP
O	339	341	of	of	IN	B-PP
O	342	346	HTLV	HTLV	NN	B-NP
O	346	347	-	-	HYPH	B-NP
O	347	348	1	1	CD	I-NP
O	348	349	;	;	:	O
O	350	353	the	the	DT	B-NP
O	354	359	modes	mode	NNS	I-NP
O	360	362	of	of	IN	B-PP
O	363	375	transmission	transmission	NN	B-NP
O	376	379	and	and	CC	O
O	380	386	global	global	JJ	B-NP
O	387	399	epidemiology	epidemiology	NN	I-NP
O	400	402	of	of	IN	B-PP
O	403	407	HTLV	HTLV	NN	B-NP
O	407	408	-	-	HYPH	B-NP
O	408	409	1	1	CD	I-NP
O	410	419	infection	infection	NN	I-NP
O	419	420	;	;	:	O
O	421	424	the	the	DT	B-NP
O	425	431	genome	genome	NN	I-NP
O	432	434	of	of	IN	B-PP
O	435	439	HTLV	HTLV	NN	B-NP
O	439	440	-	-	HYPH	B-NP
O	440	441	1	1	CD	I-NP
O	442	445	and	and	CC	O
O	446	449	the	the	DT	B-NP
O	450	459	mechanism	mechanism	NN	I-NP
O	460	462	of	of	IN	B-PP
O	463	467	HTLV	HTLV	NN	B-NP
O	467	468	-	-	HYPH	B-NP
O	468	469	1	1	CD	I-NP
O	469	470	-	-	HYPH	B-NP
O	470	477	induced	induce	VBN	I-NP
O	478	492	leukemogenesis	leukemogenesis	NN	I-NP
O	492	493	;	;	:	O
O	494	497	the	the	DT	B-NP
O	498	502	role	role	NN	I-NP
O	503	505	of	of	IN	B-PP
O	506	510	HTLV	HTLV	NN	B-NP
O	510	511	-	-	HYPH	B-NP
O	511	512	1	1	CD	I-NP
O	513	515	in	in	IN	B-PP
O	516	521	other	other	JJ	B-NP
O	522	530	diseases	disease	NNS	I-NP
O	530	531	,	,	,	O
O	532	535	and	and	CC	O
O	536	542	recent	recent	JJ	B-NP
O	543	556	breakthroughs	breakthrough	NNS	I-NP
O	557	559	in	in	IN	B-PP
B-Cancer	560	563	ATL	ATL	NN	B-NP
O	564	571	therapy	therapy	NN	I-NP
O	571	572	.	.	.	O

